NRP2 and neoplasm: The anti-tumor effects following nanoparticle-assisted delivery of tailored siRNAs directed against VEGF, NRP-2, VEGFR 2 and EGFR genes warrant further clinical investigation like toxicity to establish VEGF targeted gene therapy either alone or in combination as successful modalities for different cancer treatments.